TransMedics Group (TMDX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.44
- EPS estimate
- $0.44
- EPS surprise
- −1.08%
- Revenue surprise
- +0.01%
- Revenue
- $189.9M
- Revenue estimate
- $189.9M
- Reported
- Aug 4, 2026
TransMedics reported Q2 2026 results on August 4, 2026. Earnings per share were $0.44, matching the $0.44 estimate on the rounded figures and 1.08% below it on the source's surprise measure. Revenue was $189.9 million, in line with consensus. Compared with Q2 2025, EPS fell about 52% from $0.92, while revenue rose about 21% from $157.4 million.
The longer record shows a move from losses to profits. The company lost money in every quarter from Q3 2021 through Q3 2023, and has been profitable in each of the 11 quarters since. Annual EPS went from a $0.77 loss in 2023 to $1.01 in 2024 and $4.90 in 2025, with Q4 2025 the table's high at $2.62. Revenue rose from $241.7 million in 2023 to $605.5 million in 2025, and Q2 2026 is the highest quarter in the table. First-half 2026 EPS was $0.74, about 54% below the first half of 2025, on revenue up about 21%. TransMedics beat the EPS estimate in 13 of the last 20 quarters.
Q3 results came out between October 28 and November 9 in each of the past five years. That points to late October or early November 2026 for the next report.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | $0.44 | $0.44 | −1.08% | $189.9M | SEC |
| Q1 2026 | May 5, 2026 | $0.60 | $0.30 | −49.84% | $173.9M | SEC |
| Q4 2025 | Feb 24, 2026 | $0.44 | $2.62 | +500.37% | $160.8M | SEC |
| Q3 2025 | Oct 29, 2025 | $0.36 | $0.66 | +83.08% | $143.8M | SEC |
| Q2 2025 | Jul 30, 2025 | $0.45 | $0.92 | +104.44% | $157.4M | SEC |
| Q1 2025 | May 8, 2025 | $0.26 | $0.70 | +165.25% | $143.5M | SEC |
| Q4 2024 | Feb 27, 2025 | $0.16 | $0.19 | +19.05% | $121.6M | SEC |
| Q3 2024 | Oct 28, 2024 | $0.29 | $0.12 | −59.10% | $108.8M | SEC |
| Q2 2024 | Jul 31, 2024 | $0.21 | $0.35 | +66.03% | $114.3M | SEC |
| Q1 2024 | Apr 30, 2024 | −$0.02 | $0.35 | +2221.21% | $96.9M | SEC |
| Q4 2023 | Feb 26, 2024 | −$0.07 | $0.12 | +273.41% | $81.2M | SEC |
| Q3 2023 | Nov 6, 2023 | −$0.16 | −$0.78 | −380.89% | $66.4M | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.13 | −$0.03 | +77.06% | $52.5M | SEC |
| Q1 2023 | May 1, 2023 | −$0.25 | −$0.08 | +67.48% | $41.6M | SEC |
| Q4 2022 | Feb 22, 2023 | −$0.30 | −$0.21 | +29.86% | $31.4M | SEC |
| Q3 2022 | Nov 3, 2022 | −$0.41 | −$0.25 | +39.32% | $25.7M | SEC |
| Q2 2022 | Aug 1, 2022 | −$0.35 | −$0.41 | −17.85% | $20.5M | SEC |
| Q1 2022 | May 3, 2022 | −$0.38 | −$0.38 | +0.24% | $15.9M | SEC |
| Q4 2021 | Feb 23, 2022 | −$0.43 | −$0.46 | −6.88% | $9.7M | SEC |
| Q3 2021 | Nov 9, 2021 | −$0.36 | −$0.47 | −32.28% | $5.4M | SEC |
Quarterly revenue
Frequently asked questions
When did TransMedics Group (TMDX) last report earnings?
TransMedics Group last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did TMDX beat earnings estimates?
No. TransMedics Group reported EPS of $0.44 for Q2 2026 against a $0.44 estimate — a 1.08% miss.
How much revenue did TMDX report last quarter?
TransMedics Group reported $189.9M in revenue for Q2 2026, against a consensus estimate of $189.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.